[go: up one dir, main page]

WO2000023469A3 - Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof - Google Patents

Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof Download PDF

Info

Publication number
WO2000023469A3
WO2000023469A3 PCT/US1999/023839 US9923839W WO0023469A3 WO 2000023469 A3 WO2000023469 A3 WO 2000023469A3 US 9923839 W US9923839 W US 9923839W WO 0023469 A3 WO0023469 A3 WO 0023469A3
Authority
WO
WIPO (PCT)
Prior art keywords
igf
igfbp
subject
present
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/023839
Other languages
French (fr)
Other versions
WO2000023469A2 (en
Inventor
Steven Alan Rosenzweig
Mark James Horney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Priority to AU65154/99A priority Critical patent/AU6515499A/en
Publication of WO2000023469A2 publication Critical patent/WO2000023469A2/en
Publication of WO2000023469A3 publication Critical patent/WO2000023469A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides the portions of IGFBP and IGF peptides which account for IGF-IGFBP binding. Thus, the present invention provides an isolated IGF binding domain of an IGFBP or modifications thereof, which binds IGF with at least about the same binding affinity as the full length IGFBP. The present invention also provides an IGF antagonist that reduces binding of IGF to an IGF receptor. Further provided is a fragment of IGF or modification thereof, wherein the fragment or modification thereof binds to a binding domain of IGFBP. The present invention further provides a protein comple, comprising the IGF binding domain of IGFBP of the invention and the IGF fragment of the invention. The present invention provides methods of treating a subject with cancer and of preventing cancer in a subject, of treating a subject with a diabetic complication exacerbated by IGF and of preventing diabetic complications exacerbated by IGF comprising administering to the subject the IGF antagonist of the present invention. Also provided is a method of treating a subject with an ischemic injury or preventing an ischemic injury in a subject, comprising administering to the subject the IGF fragment or IGFBP antagonist of the invention.
PCT/US1999/023839 1998-10-16 1999-10-14 Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof Ceased WO2000023469A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65154/99A AU6515499A (en) 1998-10-16 1999-10-14 Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10452898P 1998-10-16 1998-10-16
US60/104,528 1998-10-16

Publications (2)

Publication Number Publication Date
WO2000023469A2 WO2000023469A2 (en) 2000-04-27
WO2000023469A3 true WO2000023469A3 (en) 2000-08-24

Family

ID=22300974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023839 Ceased WO2000023469A2 (en) 1998-10-16 1999-10-14 Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Country Status (2)

Country Link
AU (1) AU6515499A (en)
WO (1) WO2000023469A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
PT1141015E (en) 1999-01-06 2009-10-13 Genentech Inc Insulin-like growth factor (igf) i mutant variants
ES2301547T3 (en) 2000-05-16 2008-07-01 Genentech, Inc. TREATMENT OF CARTILAGO DISORDERS.
CN1328049A (en) * 2000-06-14 2001-12-26 上海博德基因开发有限公司 Polypeptide-insulin-like growth factor bindin 11.88 and polynucleotide for coding it
CN1328055A (en) * 2000-06-14 2001-12-26 上海博德基因开发有限公司 Polypeptide-insulin-like growth factor bindin 16.17 and polynucleotide for coding it
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
PL374181A1 (en) 2001-02-09 2005-10-03 Genentech, Inc. Crystallization of igf-1
AU2002248609B2 (en) 2001-03-14 2007-03-01 Genentech, Inc. IGF antagonist peptides
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002098914A2 (en) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Mutants of igf binding proteins and methods of production of antagonists thereof
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US6861406B2 (en) * 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
JP2007537711A (en) 2003-10-03 2007-12-27 ジェネンテック・インコーポレーテッド IGF binding protein
WO2006034832A2 (en) * 2004-09-27 2006-04-06 Univ Muenchen L Maximilians Use of igfbp-2 in senescence diseases and for the maintenance of organ functions
WO2006069765A2 (en) * 2004-12-27 2006-07-06 Geneprot Inc. Secreted polypeptide species involved in multiple sclerosis
EP2056868B1 (en) * 2006-08-16 2013-04-17 National Research Council Of Canada Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein
WO2008086813A2 (en) * 2007-01-19 2008-07-24 Kobenhavns Universitet Peptides derived from proteins of the insulin super-family
WO2009019254A1 (en) * 2007-08-03 2009-02-12 Pharis Biotec Gmbh Igfbp-2 c-terminal fragments and uses thereof
US8476408B2 (en) * 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
WO2010096125A1 (en) 2008-10-29 2010-08-26 The Rockefeller University Methods and kits for treating disease by administering insulin-like growth factor binding protein-2
EP2381774A4 (en) * 2008-12-23 2012-07-18 Salk Inst For Biological Studi METHOD OF TREATING NEURODEGENERATIVE DISEASE
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US20140286966A1 (en) * 2010-07-06 2014-09-25 Youngman Oh Methods and compositions for the treatment of metabolic syndrome, obstructive respiratory disorders, cancer and related diseases
PL2790721T3 (en) 2011-12-15 2019-05-31 Millendo Therapeutics Sas Fragments of unacylated ghrelin for use in the treatment of prader-willi syndrome
WO2013151688A1 (en) * 2012-04-06 2013-10-10 Georgia Regents University Methods and compositions for using insulin-like growth factor binding protein 6 in treating and diagnosing diabetes
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2014165137A1 (en) * 2013-03-12 2014-10-09 The University Of North Carolina At Chapel Hill Compounds and methods for treating obesity and controlling weight
EP3576767A4 (en) * 2017-02-06 2020-12-02 Academia Sinica RECOMBINANT PROTEINS AND USES THEREOF
JP6932340B2 (en) * 2019-06-21 2021-09-08 滋 天野 Cell-permeable peptide
WO2021011283A1 (en) * 2019-07-12 2021-01-21 Northwestern University Insulin like growth factor binding protein bioactive peptide fragments
CA3163851A1 (en) * 2020-03-26 2021-09-30 Desmond Mascarenhas Immodulator peptides covalently modified with small molecules
GB2620502A (en) * 2021-03-09 2024-01-10 Mascarenhas Desmond Modulation of mammalian cell lineage by synthetic immodulins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012243A1 (en) * 1991-01-08 1992-07-23 Chiron Corporation New insulin-like growth factor binding protein (igfbp-6)
WO1994022466A1 (en) * 1993-04-07 1994-10-13 Synergen, Inc. Methods of using insulin-like growth factor binding proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012243A1 (en) * 1991-01-08 1992-07-23 Chiron Corporation New insulin-like growth factor binding protein (igfbp-6)
WO1994022466A1 (en) * 1993-04-07 1994-10-13 Synergen, Inc. Methods of using insulin-like growth factor binding proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BE FORBES ET AL.,: "Localization of an insulin-like growth factor (IGF) binding site of bovine IGF binding protein-2 using disulfide mapping and deletion mutation analysis of the C-terminal domain", J. BIOL. CHEM., vol. 273, no. 8, 20 February 1998 (1998-02-20), pages 4647 - 4652, XP000882716 *
EM SPENCER AND K CHAN: "A 3-dimensional model for the insulin-like growth factor binding proteins (IGFBPs); supporting evidence using the structural determinants of the IGF binding site on IGFBP-3", PROG. GROWTH FACTOR RES., vol. 6, no. 2-4, 1995, pages 209 - 214, XP000881394 *
JF WANG ET AL.,: "Isolation of a biologically active fragment from the carboxy terminus of the fetal rat binding protein for insulin-like growth factors", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 157, no. 2, 15 December 1988 (1988-12-15), pages 718 - 726, XP000881403 *
PJ HO AND RC BAXTER: "Characterization of truncated insulin-like growth factor-binding protein-2 in human milk", ENDOCRINOLOGY, vol. 138, no. 9, September 1997 (1997-09-01), pages 3811 - 3818, XP000881395 *
SL. DROP ET AL.,: "Structural aspects of the IGFBP family", GROWTH REGUL., vol. 2, no. 2, June 1992 (1992-06-01), pages 69 - 79, XP000881414 *
X. QIN ET AL.,: "Structure-function analysis of the human insulin-like growth factor binding protein-4", J. BIOL. CHEM, vol. 273, no. 36, 4 September 1998 (1998-09-04), pages 23509 - 23516, XP000882714 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor

Also Published As

Publication number Publication date
AU6515499A (en) 2000-05-08
WO2000023469A2 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
WO2000023469A3 (en) Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
WO2002068676A3 (en) METHODS AND COMPOSITIONS FOR MODIFYING APOLIPOPROTEIN B mRNA EDITING
WO2000066138A3 (en) Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
EP1175909A3 (en) Therapeutic methods and compositions based on serrate proteins and nucleic acids
HK1040252A1 (en) Methods for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
WO2001005422A3 (en) Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
WO2001087323A3 (en) Method for treating cartilage disorders
WO2000005265A3 (en) Anti-crr2 antibodies and methods of use therefor
AU2987695A (en) Interruption of binding of mdm2 and p53 protein and therapeutic application thereof
WO2003059951A8 (en) Novel anti-igf-ir antibodies and uses thereof
ZA953629B (en) Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
WO2000001815A3 (en) Neurotrophic factors
WO2005058967A3 (en) Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
EP0728215A4 (en) METHOD OF BINDING MATERIAL TO THE -g(b)-AMYLOID PEPTIDE
DE60025008D1 (en) DETERMINATION OF ADRENOMEDULLIN-BINDING PROTEINS
WO1997009998A3 (en) Insulin-like growth factor binding protein 3 (igf-bp3) in treatment of p53-related tumors
BG103362A (en) Insulin c-peptides
EP0759441A3 (en) Methods of treating neuropeptide Y-associated conditions
WO2000071714A3 (en) Methods of reducing factor viii clearance and compositions therefor
WO2002101052A3 (en) Salutaridinol 7-o-acetyltransferase and derivatives thereof
EP0882689A3 (en) Aluminum nitride based composite body, electronic functional material, electrostatic chuck and method of producing aluminum nitride based composition body
AU4157501A (en) Her-2 binding antagonists
WO1999063086A8 (en) Insulin-like growth factor binding protein-3 variants
WO1997011968A3 (en) A gene associated with liver neoplastic disease

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 65154

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase